Advances in small molecule selective ligands for heteromeric nicotinic acetylcholine receptors
- PMID:37302724
- DOI: 10.1016/j.phrs.2023.106813
Advances in small molecule selective ligands for heteromeric nicotinic acetylcholine receptors
Abstract
The study of nicotinic acetylcholine receptors (nAChRs) has significantly progressed in the last decade, due to a) the improved techniques available for structural studies; b) the identification of ligands interacting at orthosteric and allosteric recognition sites on the nAChR proteins, able to tune channel conformational states; c) the better functional characterization of receptor subtypes/subunits and their therapeutic potential; d) the availability of novel pharmacological agents able to activate or block nicotinic-mediated cholinergic responses with subtype or stoichiometry selectivity. The copious literature on nAChRs is related to the pharmacological profile of new, promising subtype selective derivatives as well as the encouraging preclinical and early clinical evaluation of known ligands. However, recently approved therapeutic derivatives are still missing, and examples of ligands discontinued in advanced CNS clinical trials include drug candidates acting at both neuronal homomeric and heteromeric receptors. In this review, we have selected heteromeric nAChRs as the target and comment on literature reports of the past five years dealing with the discovery of new small molecule ligands or the advanced pharmacological/preclinical investigation of more promising compounds. The results obtained with bifunctional nicotinic ligands and a light-activated ligand as well as the applications of promising radiopharmaceuticals for heteromeric subtypes are also discussed.
Keywords: Allosteric nicotinic modulators; Dual-acting nicotinic ligands; Heteromeric nAChRs; Light-regulated nicotinic ligands; Nicotinic acetylcholine receptors (nAChRs); Nicotinic radiopharmaceuticals; Orthosteric nicotinic agonists; Orthosteric nicotinic antagonists.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The Authors declare that they have no competing interests.
Similar articles
- Contrasting properties of α7-selective orthosteric and allosteric agonists examined on native nicotinic acetylcholine receptors.Gill JK, Chatzidaki A, Ursu D, Sher E, Millar NS.Gill JK, et al.PLoS One. 2013;8(1):e55047. doi: 10.1371/journal.pone.0055047. Epub 2013 Jan 29.PLoS One. 2013.PMID:23383051Free PMC article.
- Orthosteric and allosteric potentiation of heteromeric neuronal nicotinic acetylcholine receptors.Wang J, Lindstrom J.Wang J, et al.Br J Pharmacol. 2018 Jun;175(11):1805-1821. doi: 10.1111/bph.13745. Epub 2017 Mar 20.Br J Pharmacol. 2018.PMID:28199738Free PMC article.Review.
- Diverse strategies targeting α7 homomeric and α6β2* heteromeric nicotinic acetylcholine receptors for smoking cessation.Brunzell DH, McIntosh JM, Papke RL.Brunzell DH, et al.Ann N Y Acad Sci. 2014 Oct;1327(1):27-45. doi: 10.1111/nyas.12421. Epub 2014 Apr 14.Ann N Y Acad Sci. 2014.PMID:24730978Free PMC article.Review.
- Allosteric modulation of nicotinic acetylcholine receptors.Chatzidaki A, Millar NS.Chatzidaki A, et al.Biochem Pharmacol. 2015 Oct 15;97(4):408-417. doi: 10.1016/j.bcp.2015.07.028. Epub 2015 Jul 29.Biochem Pharmacol. 2015.PMID:26231943Review.
- Effects of neuronal nicotinic acetylcholine receptor allosteric modulators in animal behavior studies.Pandya AA, Yakel JL.Pandya AA, et al.Biochem Pharmacol. 2013 Oct 15;86(8):1054-62. doi: 10.1016/j.bcp.2013.05.018. Epub 2013 May 31.Biochem Pharmacol. 2013.PMID:23732296Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Miscellaneous